Verona Pharma PLC ADR (VRNA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | David S. Zaccardelli |
| Employees: | 30 |
| Web site: | veronapharma.com |
|
3 MORE LONDON RIVERSIDE, LONDON, X0, SE1 2RE
011-44-0-2032834200
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Verona Pharma plc focuses on development and commercialization of therapies for respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes. Enfentrine is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Please log in first to see chart